Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma
Authors:
- 1 August 2020
- journal article
- letter
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 415, 116972
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York StateJAMA, 2020
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19New England Journal of Medicine, 2020
- Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm SocietyIndian Pacing and Electrophysiology Journal, 2020